Skip to main content
. 2015 Aug;149(2):481–492.e7. doi: 10.1053/j.gastro.2015.04.015

Figure 4.

Figure 4

GSK-7975A markedly reduces all biochemical responses of TLCS-AP, CER-AP, and FAEE-AP. All models resulted in substantial increases of (A) serum amylase, (B) IL6, (C) pancreatic trypsin activity, (D) pancreatic activity, and (E) lung MPO activity. Subcutaneous osmotic minipump administration of GSK-7975A given as prodrug GSK-6288B at low (L) or high (H) doses significantly reduced all parameters, with a more marked reduction of serum amylase and IL6, pancreatic trypsin at the high dose (mean ± SEM ≥6 mice/group; *P < .05, control vs 3 models; †P < .05 TLCS-AP vs TLCS-AP plus GSK-7975A; ‡P < .05, CER-AP vs CER-AP plus GSK-7975A; and §P < .05, FAEE-AP vs FAEE-AP plus GSK-7975A).